



Rani Therapeutics Appoints Talat Imran CEO

June 22, 2021

San Jose, CA | June 22, 2021 11:00 AM Eastern Daylight Time

Rani Therapeutics, a disrupter in oral biologics, today announced the appointment of Talat Imran to Chief Executive Officer. Mir Imran, the company's founder and former CEO, will become Executive Chairman.

"Talat has extensive experience in corporate development and fundraising and has been actively involved in Rani's key strategic decisions for many years. His appointment as CEO is a natural evolution of the leadership he has demonstrated during his tenure with the company," said Maulik Nanavaty, Rani Board member. "We are incredibly grateful for Mir's many contributions to the company, and his commitment and leadership since founding Rani."

"I am honored to be appointed CEO of Rani Therapeutics – a company that I believe has the potential to reinvent, disrupt and expand the biologics industry as we currently know it," said Talat Imran, Rani's CEO. "Mir has an amazing track record of innovation and entrepreneurship, and I'm delighted that he will continue to be engaged with the further development of our RaniPill™ platform."

Talat has been a key member of Rani's executive team since 2014, most recently serving as the company's Vice President, Strategy. In addition to his role at Rani, Talat has been a venture capitalist with several healthcare-focused Silicon Valley funds, including InCube Ventures, LP, and VentureHealth. Previously, he also served as Chief Executive Officer of Venture Web Partners, a web application development firm.

"We believe passionately in our goal of transforming the lives of millions of patients who currently must endure injectable therapies," said Mir Imran, Rani's founder and Executive Chairman. "Talat deeply understands Rani's business and the opportunities that lay ahead of us, and he is uniquely positioned to lead and guide us through the next stages of our development."

About Rani Therapeutics

Rani Therapeutics is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe will have the potential to transform medicine and improve patient outcomes. The company has developed the RaniPill™ capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill™ capsule.

Investor Contact:

investors@ranitherapeutics.com

Media Contact:

rani-therapeutics@consortpartners.com

Contact Details

Consort Partners

rani-therapeutics@consortpartners.com